These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7318880)

  • 1. Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
    Anderson P; Norbeck HE
    Eur J Clin Pharmacol; 1981; 21(3):209-14. PubMed ID: 7318880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
    Ledermann H; Kaufmann B
    J Int Med Res; 1981; 9(6):516-20. PubMed ID: 7319135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
    Abshagen U; Spörl-Radun S; Marinow J
    Eur J Clin Pharmacol; 1980 Apr; 17(4):305-8. PubMed ID: 6995131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.
    Abshagen U; Kösters W; Kaufmann B; Lang PD
    Klin Wochenschr; 1980 Sep; 58(17):889-96. PubMed ID: 7442088
    [No Abstract]   [Full Text] [Related]  

  • 5. Bezafibrate: lack of effect on creatinine excretion and muscular proteins.
    Mertz DP; Lang PD; Vollmar J
    Res Exp Med (Berl); 1982; 180(1):95-8. PubMed ID: 7079594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
    Dick TB; Marples J; Ledermann HM; Whittington J
    Curr Med Res Opin; 1981; 7(8):489-502. PubMed ID: 7030635
    [No Abstract]   [Full Text] [Related]  

  • 7. "In vitro" metabolism of bezafibrate by rat liver.
    Maffei FR; Carini M; Bertuletti R; Tofanetti O
    Pharmacol Res Commun; 1981 Feb; 13(2):121-32. PubMed ID: 7220572
    [No Abstract]   [Full Text] [Related]  

  • 8. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of uremic hypertriglyceridaemia with bezafibrate.
    Norbeck HE; Anderson P
    Atherosclerosis; 1982 Aug; 44(2):125-36. PubMed ID: 7138614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs.
    Garrett ER; Altmayer P
    J Pharm Sci; 1985 Mar; 74(3):295-9. PubMed ID: 4009437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of bezafibrate on biliary lipids (author's transl)].
    Schlierf G; Fischer H; Roche A; Stiehl A; Oster P; Schellenberg B; Vollmar J
    MMW Munch Med Wochenschr; 1980 Feb; 122(5):165-8. PubMed ID: 6767944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Szostak WB
    Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The short- and long-term effects of bezafibrate in the rat.
    Fahimi HD; Reinicke A; Sujatta M; Yokota S; Ozel M; Hartig F; Stegmeier K
    Ann N Y Acad Sci; 1982; 386():111-35. PubMed ID: 6953842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute muscular syndrome after bezafibrate.
    Bock KD
    Klin Wochenschr; 1981 Dec; 59(23):1321. PubMed ID: 7311399
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic effects of bezafibrate in hyperlipidemia].
    Kunesová M; Honková M; Zeman M; Mares P; Skorepa J
    Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789
    [No Abstract]   [Full Text] [Related]  

  • 18. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
    Lageder H
    Wien Klin Wochenschr; 1980 Feb; 92(3):95-101. PubMed ID: 6985560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bezafibrate in primary hyperlipidemias (author's transl)].
    Wechsler JG; Hutt V; Klör HU; Bode G; Ditschuneit H
    Klin Wochenschr; 1982 Jan; 60(2):97-105. PubMed ID: 7070008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.